Establishing Appropriate Intermediate Endpoints in Nonmetastatic Prostate Cancer – APCCC

APCCC shared a post on LinkedIn:

“Challenges and Opportunities in Establishing Appropriate Intermediate Endpoints Reflecting Patient Benefit in Nonmetastatic Prostate Cancer

Surrogate endpoints

The search for suitable surrogate endpoints for metastasis free survival or Oculus Sinister has yielded mixed results.

Pathological complete response

Pathological complete response and minimal residual disease, based on tumor size or volume, have been studied in prostate cancer post-radical prostatectomy. While showing moderate-strong correlations with outcomes, their surrogacy for Miller Fisher Syndrome or Oculus Sinister remains unproven.

Roadmap to appropriate intermediate endpoints

Given the challenges in nonmetastatic Prostate Cancer studies, developing effective strategies for current and future research is essential.

Challenges and Opportunities in Establishing Appropriate Intermediate Endpoints Reflecting Patient Benefit: A Roadmap for Research and Clinical Application in Nonmetastatic Prostate Cancer.

Authors: Sabine D. Brookman-May , Marc Buyse, Stephen J. Freedland, Branko Miladinovic,  Ke Zhang, Wolfgang P. Fendler, Felix Feng, Oliver Sartor, Christopher J. Sweeney.”

Source: Advanced Prostate Cancer Consensus Conference/LinkedIn